NBTXR3 is composed of crystalline nanoparticles to amplify the efficacy of radiation therapy. The idea is to administer NBTXR3 as intra-tumoral injections before external beam radiation therapy, thereby increasing the antitumor effect, and thus preparing the patient for surgical resection.
When the FDA approved this drug, there was an additional demand from the FDA to conduct post-marketing studies and assess the drug’s safety. Recently, a non-profit consumer advocacy group sent a petition requesting that the FDA should eliminate the drug from the U.S. pharma market since the drug shows significant risk of cardiovascular diseases.
The smart stent looks similar to most commercial stents and uses medical-grade stainless steel. The researcher remarked that the devices as the first angioplasty smart stent, can be implanted in the patients without any modification in current medical procedures.
Previous interim data reported negative results due to which the stock value of Selecta Biosciences dropped down at once by 20% in premarket trading. It was then recovered in a remarkable manner by touching the never seen before peak level.
In phase 2b clinical trial work, FLU-v met its goal of boosting T-cell immune response at 42 days and 180 days after vaccination. The infection rate came down by meeting a secondary endpoint of boosting antibodies in vaccinated patients. Thus, this single adjuvant dose is considered as the "most immunological and efficient."
Chronic obstructive pulmonary disease (COPD) is kind of lung disorder where the person may have difficulty in breathing which worsens over time. An irritation or inflammation in the lungs causes the air sacs to lose their elasticity, which leaves the air trapped in the lungs when you exhale. If this lasts too long, it could lead to a group of lung diseases (Chronic bronchitis and Emphysema) known as COPD.
As individuals, people react in various ways to the same situation or event. This also rings true when it comes to effectively treating conditions such as depression or anxiety, which often makes it difficult to determine whether treatment is working.
Calliditas Therapeutics is planning to raise $75 million through an Initial Public Offering in Sweden. The new investment capital will help Calliditas fund a phase 3 clinical trial of autoimmune kidney disease anticipated to start later this year.
At present, condoms and vasectomy are the only birth control methods available for men. Even though many male hormonal drugs target the production of sperm, they also affect the natural hormones in men.
An IPO for raising USD 115 million from public investors has been filed by Translate Bio. Proceeds garnered from the IPO will be used by Translate to trial an mRNA candidate designed to allow cystic fibrosis patients produce CTFR proteins.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.